# Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

> **NCT01536691** · PHASE3 · UNKNOWN · sponsor: **Hallym University Medical Center** · enrollment: 338 (estimated)

## Conditions studied

- Cancer
- Malignancy

## Interventions

- **DRUG:** ramosetron
- **DRUG:** ondansetron

## Key facts

- **NCT ID:** NCT01536691
- **Lead sponsor:** Hallym University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2012-11
- **Final completion:** 2013-02
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2012-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536691, "Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01536691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*